Not to be released, published, distributed or circulated in any jurisdiction in which it would be unlawful to do so. This ...

Not to be released, published, distributed or circulated in any jurisdiction in which it would be unlawful to do so. This ...

Learn more about whether Alvotech or Arrowhead Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Alvotech (NASDAQ: ALVO, the “Company”) has entered into agreement with DNB Carnegie Investment Bank AB (publ) (“DNB Carnegie” ...

REYKJAVIK, Iceland, May 7, 2025 - Alvotech (NASDAQ: ALVO, or the "Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...

REYKJAVIK, ICELAND AND STOCKHOLM, SWEDEN (May 16, 2025) - Alvotech (NASDAQ: ALVO, the "Company"), a global biotech company specializing in the development and manufacture of biosimilar medicines ...

Kaddis said insurers are locked in a cat-and-mouse game with drugmakers as the insurance sector invests in biosimilars and ...

Alvotech's stock has dropped significantly due to potential tariffs and ongoing profitability challenges, despite strong revenue growth and a promising biosimilar pipeline. The company's reliance ...

Selardsdi is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and ...